Emily Conley, Racquel Bracken (Federation Bio)
Venrock takes the wrap off its first microbiome startup, armed with $50M, a CEO from 23andMe and two founders from Stanford
Venrock has largely stayed on the sidelines of the microbiome space, watching with keen interest as fellow VCs and Big Pharma alike put money and resources behind the idea of harnessing human gut bacteria as drugs. Biotechs have made headway by either processing donor feces into “crapsules,” zeroing in on a handful of strains as therapeutics, or genetically engineering bugs to enhance their effect. But the platforms were often wanting.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
